期刊文献+

SPAG5在原发性乳腺癌中的表达与TEC方案新辅助化疗敏感性的关系 被引量:3

Correlation between expression of SPAG5 and the sensitivity to TEC regimens neoadjuvant chemotherapy in primary breast cancer
暂未订购
导出
摘要 目的观察精子相关抗原5(SPAG5)在乳腺癌组织中的表达,探讨其表达情况与临床病理因素及TEC方案(T:多西他赛,E:表柔比星,C:环磷酰胺)新辅助化疗疗效之间的关系。方法收集107例接受TEC方案新辅助化疗的乳腺癌患者化疗前的组织标本,通过免疫组织化学法检测各标本中SPAG5蛋白的表达,结合临床病理因素及新辅助化疗疗效进行分析。结果 107例原发性乳腺癌组织中SPAG5蛋白高表达率48.6%(52/107),与人类表皮生长因子受体2过表达呈正相关性(P=0.000),与细胞增殖核抗原过表达呈正相关性(P=0.019)。SPAG5的表达在患者年龄、肿瘤大小、肿瘤分期、组织学分级、淋巴结状况、雌激素受体及孕激素受体的表达情况中均差异无统计学意义。化疗总体客观缓解(OR)率为70.1%(75/107),其中病理完全缓解(p CR)率9.3%(10/107),SPAG5高表达组OR率为82.7%(43/52),低表达组56.1%(32/57),差异有统计学意义(P=0.006)。SPAG5高表达组p CR率为15.4%(8/44),SPAG5低表达组p CR率为3.6%(2/53),差异有统计学意义(P=0.048)。结论 SPAG5作为肿瘤增殖指标,其表达状态对于乳腺癌患者TEC方案新辅助化疗的疗效具有预测作用。 Objective To explore the expression of sperm associated antigen5 (SPAG5) and discuss the relation- ship between expression, clinieopathologic characteristics and sensitivity to neoadjuvant chemotherapy in primary breast cancer. Methods The tissue of 107 patients treated with TEC(T:Docetaxel E:Epirubicin C:Cytoxan) neo- adjuvant chemotherapy with primary breast cancer were collected to measure the expression of SPAG5 by immuno- histochemical staining. Data were analysed to investigate the correlation to clinicpathologic factors and chemothera- pyresponse. Results The over-expressed rate of SPAG5 from tissues of primary breast cancer was 48.6% (52/ 107 ) and proved to be positively correlated to the over-expression of human epidermal growth factor receptor-2( P = 0. 000) and proliferating cell nuclear antigen( P = 0. 019 ). However there were no significant correlations between age, tumor size, TNM stage, histological grading,lymphnode status and the expression level of estrogen receptor and progesterone receptor. The overall objective response(OR) rate was 70. 1% (75/107) and the pathologic complete response(pCR) rate was 9.3% (10/107)after neoadjuvant chemotherapy. The objective response rates were 82.7% (43/52) in SPAG5 over-expression group and 56. 1% (32/57) in low-expression group, and the difference was statistically significant(P = 0. 006). The rates of pCR were 15.4% (8/44) in group of SPAG5 over-expression and 3.6% (2/53)in low-expression group, which proved significantly different by Fisher exact probability test( P = 0. 048 ). The OR rate and pCR rate of patients with over-expression of SPAG5 were higher than low-expression ones. Conclusion SPAG5 as a tumor proliferation index, its expression status for breast cancer patients with TEC regimen neoadjuvant chemotherapy has a predictive effect.
出处 《安徽医科大学学报》 CAS 北大核心 2017年第11期1704-1708,共5页 Acta Universitatis Medicinalis Anhui
基金 国家自然科学基金(编号:81472493) 安徽省自然科学基金(编号:1608085MH238)
关键词 SPAG5 增殖指标 乳腺肿瘤 新辅助化疗 TEC SPAG5 proliferation breast neoplasms neoadjuvant chemotherapy TEC
  • 相关文献

同被引文献16

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部